{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057831","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.468668+00:00","generated_at":"2026-06-02T03:49:56.815417+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Iterum CMO Sailaja Puttagunta resigns effective May 31; Steven Aronin to lead clinical development","bullets":["CMO Sailaja Puttagunta resigns for personal reasons, effective May 31, 2024; no disagreement with company.","Dr. Puttagunta will remain as consultant during regulatory review of oral sulopenem NDA for uncomplicated UTI.","Steven Aronin, SVP and Head of Clinical Development, will assume leadership of development and regulatory activities.","Transition occurs during FDA review of resubmitted NDA for oral sulopenem; potential impact on timeline."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057831","json":"https://secwatch.observer/filing/0000950170-24-057831.json","markdown":"https://secwatch.observer/filing/0000950170-24-057831.md","text":"https://secwatch.observer/filing/0000950170-24-057831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024057831/0000950170-24-057831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024057831/itrm-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:49:56.815417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d97c8b118","claim":"Sailaja Puttagunta resigned as Chief Medical Officer at Iterum Therapeutics plc.","evidence_excerpt":"On May 8, 2024, Sailaja Puttagunta M.D. notified Iterum Therapeutics plc (the “Company”) of her decision to resign as Chief Medical Officer the Company, effective May 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024057831/0000950170-24-057831-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}